Skip to main content

Table 1 Estimates of SpikeVaxâ„¢ vaccine efficacy against infection, symptomatic disease, and severe disease caused by the original and Alpha variants of SARS-CoV-2 virus [25,26,27,28,29]

From: Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study

Efficacy against (%)

Infection

(95% CI)

Symptomatic infection

(95% CI)

Severe disease

(95% CI)

Variant

14 d after dose 1

7 d after dose 2

14 d after dose 1

7 d after dose 2

14 d after dose 1

7 d after dose 2

Original

61 (31—79)

93.3 (85.7—97.4)

92.1 (68.8—99.1)

94.1 (89.3—96.8)

92.1 (68.8—99.1)

100

Alpha

54.7 (44.8—62.9)

86 (81—90.6)

88.1 (83.7—91.5)

91 (84—95)

81.6 (71.0—88.8)

95.7 (73.4—99.9)